Third agent

Phase 3Small molecule

Gilead

Third agent is one of 9 small molecule programs targeting Tenofovir. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TenofovirActive, not recruiting

TenofovirPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Tenofovir

#DrugCompanyPhaseTrials

Tybost

Gilead

Phase 3

6 2

B/F/TAF

Gilead

Phase 3

2 3

ISL/LEN

Gilead

Phase 3

1 4

PTM SEMA

Gilead

Phase 3

1 5

Cobicistat TOS

Gilead

Phase 3

1 6

F/TAF

Gilead

Phase 3

1 7

Lpv/r

Gilead

Phase 3

1 8

Third agent

Gilead

Phase 3

2 9

Truvada

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Active, not recruiting

Tenofovir

NCT02016924

Clinical

Trials by Indication[1]

Tenofovir2 trials

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Completed· Gilead logo

Gilead·Phase 3·NCT03631732·496 enrolled

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruiting· Gilead logo

Gilead·Phase 2/3·NCT02016924·133 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Completed· Gilead logo

Gilead·Phase 3·NCT02605954·275 enrolled

Tenofovir Disoproxil Fumarate1 trial

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Completed· Gilead logo

Gilead·Phase 3·NCT02616783·167 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Third agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Third agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Third agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

Third agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Tenofovir2 trials

Safety and Efficacy1 trial

Tenofovir Disoproxil Fumarate1 trial

References

Drug Info

Quick Facts

Related News